New Preclinical Data Evaluating Innovative Compounds will be presented Growing Research and Development by x29Gd4

VIEWS: 6 PAGES: 6

									Not intended for U.S. and UK Media


103rd Annual Meeting American Association for Cancer Research:

Bayer to Present New Data on Oncology Pipeline

   New Preclinical Data Evaluating Innovative Compounds will be presented
   Growing Research and Development Portfolio


Berlin, March 28, 2012 – Bayer HealthCare today announced that the company will
present latest preclinical data that introduce investigational compounds for both therapy
and imaging in its oncology pipeline at the American Association for Cancer Research
(AACR) 103rd Annual Meeting, March 31 - April 4, 2012, in Chicago, IL. The annual
AACR meeting highlights the latest findings in all major areas of cancer research.


This includes currently at Bayer developed investigational agents such as an antibody-
drug conjugate (ADC, BAY 94-9343) and a phosphatidylinositol 3-kinase (PI3K) inhibitor
(BAY 80-6946). The antibody-drug conjugate Mesothelin-ADC is being developed to
target the antigen mesothelin which is selectively expressed on certain tumors.
Mesothelin-ADC is developed in collaboration with ImmunoGen Inc. The PI3K inhibitor
targets a lipid kinase involved in crucial cellular functions such as tumor cell proliferation
and survival signaling. Both investigational agents are now in early clinical development
(Phase I) at Bayer.


"Cancer is a complex disease process and as our understanding of these signaling
mechanisms deepens, so does our ability to develop innovative, targeted approaches to
combat this disease,” said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group
Oncology/Gynecological Therapy at Bayer HealthCare. “The research data presented at
this oncology research conference shows our commitment toward developing a wide
variety of investigational agents against signaling pathways with the goal to treat cancer
more effectively so patients can live longer.“




                                           - 1/6 -
Bayer has established a broad network with external partners in the area of oncology.
Preclinical data from joint projects will be presented at the upcoming AACR meeting in
Chicago, such as the bispecific BiTE® antibody (MT112/ BAY 2010112) targeting a
prostate specific antigen which is currently being developed in collaboration with Amgen.
A strategic partnership with the German Cancer Research Center (DKFZ) focuses on the
translation of findings from research into innovative drugs and highlights of preclinical
data from this partnership, like the characterization of DNA methyltransferase 3B, will also
be presented at the AACR meeting. Another of Bayer’s partners, OncoMed
Pharmaceuticals Inc., will present new preclinical data on a Frizzled/Wnt pathway
antagonist antibody OMP-18R5.


Additionally, preclinical data will also be presented on regorafenib (BAY 73-4506) and
Alpharadin (radium-223 chloride), two investigational agents in late stage clinical
development at Bayer.


Alpharadin (radium-223 chloride) is an investigational alpha-pharmaceutical in clinical
development for cancer patients with bone or skeletal metastases. This investigational
agent mimics calcium and targets radium-223 to areas of high bone deposition in and
around bone metastases and is developed together with Algeta ASA. It has shown an
increase in overall survival in patients with castration-resistant prostate cancer (CRPC)
and symptomatic bone metastasis in a pivotal Phase III trial. Alpharadin has been granted
Fast Track status by the U.S. Food and Drug Administration (FDA).


Regorafenib, a novel oral multi-kinase inhibitor of tumor neoangiogenesis is currently
being investigated in clinical trials for its potential to treat patients with various tumor
types. Regorafenib has shown an increase in overall survival in a Phase III trial in patients
with metastatic colorectal cancer who have progressed after approved therapies,
including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR
therapy if KRAS WT. The study was stopped early after an interim analysis which resulted
in a statistically significant improvement of overall survival. Another ongoing Phase III trial
in patients with tyrosine kinase inhibitor refractory gastrointestinal stromal tumors (GIST)
is ongoing. The FDA has granted regorafenib Fast Track status for both indications. For
GIST, regorafenib has also been granted "Orphan Drug Status”. In 2011, Bayer entered
into an agreement with Onyx Pharmaceuticals, Inc. under which Onyx will receive a
royalty on any future global net sales of regorafenib in oncology.



                                           - 2/6 -
Data on two PET tracers L-5-F-18-ethoxy-Tryptophan for tumor specific imaging and
FSPG (BAY 94-9392), a derivative of L-glutamate for improved diagnosis and staging of
certain tumor types will also be shown at the conference.


A total of 15 abstracts evaluating investigational agents in Bayer’s pipeline will be
presented at AACR.


Poster Presentations
• Tumor specific imaging by L-5-F-18-ethoxy-Tryptophan mediated by LAT1 and IDO1
   o Presentation #360, Session: Imaging of Molecular and Cellular Events in Tumors
      and Tumor Cells
   o Sunday, April 1, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
      Section 13

• Comparison of commercially available phosphorylated ERK antibodies for
  immunohistochemical biomarker analysis
   o Presentation #742, Session: Clinical Trials in Radiation Oncology / Regulatory
     Science
   o Sunday, April 1, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
     Section 27

• Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK
  inhibitor BAY 86-9766 in preclinical biliary tract cancer models.
    o Presentation #869, Session: Kinase and Phosphatase Inhibitors 1
    o Sunday, April 1, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
      Section 32

• Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with
  DNA demethylation.
   o Presentation #1036, Session: Chromatin Regulators
   o Monday, April 2, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
      Poster Section 1

• Regorafenib (BAY 73-4506): Anti-metastatic activity in a mouse model of colorectal
  cancer.
   o Presentation #2337, Session: Angiogenesis Inhibitors
   o Monday, April 2, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
     Section 12




                                          - 3/6 -
    • Efficacy and Candidate Biomarker Evaluation for the anti-Mesothelin antibody drug
      conjugate BAY 94-9343, Mesothelin-ADC in Mesothelin positive preclinical xenograft
      models.
       o Presentation #2726, Session: Biological Therapy Based on Viruses, Antibodies, or
           Metformin
       o Monday, April 2, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
           Section 28

    • BAY 1082439, a highly selective and balanced PI3K/ inhibitor demonstrated potent
      activity in tumors with activated PI3K and loss-of-function of PTEN.
       o Presentation #2799, Session: Kinases as Targets for Therapy
       o Monday, April 2, 2012, 1:00 p.m.-5:00 p.m., McCormick Place West (Hall F), Poster
          Section 31

    • CD24 regulates tumor cell behaviour in a c-Src dependent fashion.
       o Presentation #3087, Session: Cross-Talk between Signaling Pathways and
         Transcription Factors
       o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
         Poster Section 4

    • Development of a novel Wnt pathway antagonist antibody, OMP-18R5 that reduces
      tumor initiating cell frequency in breast cancer.
        o Presentation #3356, Session: Identification and Targeting of Cancer Stem Cells
        o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
          Poster Section 14

    • Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY
      2010112 leads to complete remission of human prostate cancer xenografts in mice.
       o Presentation #3526, Session: Mobilizing Immune Effector Cells for Cancer Therapy
       o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
         Poster Section 19

•     In vitro and in vivo pharmacological profile of BAY 1001931, a novel highly potent
      allosteric AKT1/2 inhibitor.
        o Presentation #3751, Session: Kinase Inhibitors
        o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
           Poster Section 29

    • BAY 87-2243, an inhibitor of HIF1-induced gene activation, showed promising anti-
      tumor efficacy in combination with anti-angiogenic therapy and irradiation in preclinical
      tumor models.
        o Presentation #LB-244, Session: Late-Breaking Research: Experimental and
          Molecular Therapeutics 1
        o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
          Poster Section 39




                                             - 4/6 -
• Pilot clinical trials of FSPG (BAY 94-9392): An 18F-labeled glutamate derivative for
  PET imaging of system xC-activity in tumors.
   o Presentation #LB-227, Session: Late-Breaking Research: Clinical Trials
   o Tuesday, April 3, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
      Poster Section 40

• LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell
  lung cancer
    o Presentation #5605, Session: Cytoplasmic Kinases and Drug Resistance
    o Wednesday, April 4, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
      Poster Section 29

• Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and
  increases survival in a mouse model of breast cancer bone metastases in preventive
  and micro-metastatic settings
    o Presentation #5712, Session: Preclinical Radiotherapeutics
    o Wednesday, April 4, 2012, 8:00 a.m.-12:00 p.m., McCormick Place West (Hall F),
      Poster Section 34

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health
care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative
companies in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health, Consumer
Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to
discover, develop, manufacture and market products that will improve human and animal
health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. Find more information at
www.bayerhealthcare.com.



Contact:
Kerstin Crusius, Tel. +49 30 468 14726
E-Mail: kerstin.crusius@bayer.com


Find more information at www.bayerpharma.com.
kc          (2012-0136E)




                                         - 5/6 -
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer
Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation, development or performance of the company
and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on
the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.




                                                      - 6/6 -

								
To top